Lightning Round: QXO is a buy, says Jim Cramer
Speakers
Jim Cramer
— Host, Mad Money
Summary
Jim Cramer's Lightning Round covers QXO, Viking Therapeutics, Eli Lilly, and Starfighters Space. Cramer says QXO is a buy, citing its $2 billion convertible preferred and Brad Jacobs. He prefers Eli Lilly over Viking Therapeutics and treats Starfighters Space as an uber-speculative IPO.
- Cramer says QXO is a buy despite the stock's rise.
- He cites QXO's $2B convertible preferred as a possible floor.
- He sticks with Eli Lilly over Viking Therapeutics.
- Viking Cruises is mentioned only as a joke alternative.
- Starfighters Space/FJET is framed as an uber-speculative IPO.
- The segment is a Lightning Round stock call-in format.
- A coming segment will examine White House industry interventions.
Ideas
QXO buy; Brad Jacobs preferred floor
Cramer says QXO is a buy. He points to $2 billion in convertible preferred as a potential floor and argues you cannot bet against Brad Jacobs. He says he will not pound the table just because the stock is up, but still thinks it is a buy.
Stick with Eli Lilly over Viking
Cramer says he is an Eli Lilly guy and is going to stick with it, preferring Eli Lilly over Viking Therapeutics when asked about the biotech name.
FJET is an uber spec, small allocation
Cramer calls Starfighters Space FJET an uber spec and says there is room for uber-speculative positions, implying it is a highly volatile new aerospace IPO suitable only for a small speculative allocation.
Up Next
This CNBC video, published January 09, 2026, features Jim Cramer discussing QXO, LLY, FJET. 3 trade ideas extracted by AI with direction and confidence scoring.
Speakers: Jim Cramer · Tickers: QXO, LLY, FJET